This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Validity of estimate of measure of effectiveness
The clinical evidence came from a clinical trial, which was appropriate for the study question. The use of assessment blinding and intention to treat analysis, and the multi-centre nature of the study enhances the internal validity of the analysis. However, neither the patients nor the physicians were blinded to treatment allocation, which could have introduced some bias, for example in the interpretation of side effects. Nevertheless, the authors pointed out that this should have favoured newer drugs. Further, the study was powered to detect statistically significant differences between the groups. The study groups were balanced at baseline, which improves the validity of the comparison. Statistical analyses were carried out to account for the potential impact of confounding factors, such as some baseline characteristics of the patients enrolled. Statistical techniques were used to take missing data into consideration. More details of the clinical trial might be found in the primary publication. A limitation of the clinical analysis was that, as the authors noted, there was insufficient information to determine whether the patients who participated in the trial were representative of eligible patients requiring a change in medication. Thus, caution will be required when considering the representativeness of this patient population.
Validity of estimate of measure of benefit
QALYs are an appropriate benefit measure of the impact of the interventions on patient health since the analysis focused on health-related quality of life, which is a relevant dimension of health for patients with schizophrenia. QALYs are also comparable with the benefits of other health care interventions. The authors stated that the EQ-5D is a validated instrument for people with schizophrenia.
Validity of estimate of costs
The analysis of the costs was consistent with the perspective adopted in the study. A breakdown of the cost items was given. Extensive details of resource quantities were provided, but the unit costs were not reported. The costs were derived from typical UK sources and the use of alternative sources was investigated in the sensitivity analysis. Statistical analyses were carried out to deal with the skewed distributions of the resources used. The price year was reported, thus facilitating reflation exercises in other time periods. The authors stated that the exclusion of costs of contacts with the criminal justice system, use of residential accommodation and informal care, might have resulted in an underestimation of total costs, although the amount of these items should have been limited over the trial observation period.
Other issues
The authors stated that their findings agreed with the conclusions of two UK-based economic modelling studies, although many studies suggest that SGAs may be cost-effective. The authors noted that the issue of missing clinical and economic data could have affected the robustness of the analysis, although the sensitivity analysis showed that the use of alternative imputation methods did not alter the results of the study. In addition, extensive statistical tests were carried out to address the issue of uncertainty. Another drawback of the analysis was the fact that the study had insufficient power to detect statistically significant differences in QALYs and costs.
Implications of the study
The study results do not support the widespread use of SGAs for the treatment of schizophrenia. The authors concluded that "further observational and pragmatic trials are required to identify cost-effective antipsychotic use, the determinants of costs and outcomes and the roles of first-and second-generation antipsychotic drugs in long-term management". 
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